Prot# SB-275833/032: A Rndmzd, Dbl-Blnd, Dbl-Dummy, Mltcntr, Non-Inferiority Phase III Study to Assess the Safety & Efficacy of Topical 1% SB-275833 Ointment, Applied 2x Daily, v. Oral Cephalexin, 500mg in Adults, or 12.5mg/kg(250mg/5mL)in Child

Project: Research project

Project Details

StatusFinished
Effective start/end date9/1/04 → 6/22/06

Funding

  • GlaxoSmithKline plc (SB-275833/032)